Fig. 2: Immunogenicity of H1 stem nanoparticle variants in mice.

BALB/c mice (N = 10) were immunized with 2 µg of H1ssF WT, H1ssF gN38 or H1ssF R38 on weeks 0, 4, and 8. Serum antibody titers to HAs were measured at 2 weeks after the third immunization (week 10). a ELISA endpoint titers to H1N1 NC99 HA (left) and its gN38 variant (right). b Serum neutralizing antibody titers to NC99, SG86, and CA09 (H1N1) pseudoviruses. Shown are half-maximal inhibitory dilution of serum (IC50). c ELISA endpoint titers to H5N1 VN04 (left) and H7N9 AN13 HAs (right). d Serum neutralizing antibody titers to H5N1 VN04 and H7N9 AN13 pseudoviruses. Dotted lines indicate the lower detection limit of the assay. Data are presented as scattered dot plots with horizontal lines indicating geometric mean for each group. Statistical analysis was carried out by using nonparametric Kruskal–Wallis test with Dunn’s multiple comparisons. Displayed results are representative of two independent experiments (H1ssF WT and H1ssF gN38) or based on one experiment (H1ssF R38). Source data are provided as Source Data file.